Loading...

PerCP/Cyanine5.5 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
  • 53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100733 25 µg 70€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100734 100 µg 190€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/mL
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is < 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  2. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  3. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  4. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  5. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  6. Yoon J et al. 2018. J Vis Exp. -141 . PubMed
  7. Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed
  8. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  9. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  10. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  11. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
  12. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  13. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  14. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  15. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  16. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  17. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  18. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  19. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  20. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  21. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  22. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  23. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  24. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  25. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  26. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  27. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  28. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  29. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  30. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  31. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  32. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  33. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  34. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  35. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  36. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  37. Juul-Madsen K, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  38. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  39. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  40. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  41. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  42. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  43. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  44. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  45. Hong JY, et al. 2020. Cell. 180(5):847-861. PubMed
  46. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  47. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  48. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  49. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  50. Solanki A, et al. 2018. Development. 145. PubMed
  51. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  52. Green DP, et al. 2019. Neuron. 101:412. PubMed
  53. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  54. Smith AS, et al. 2022. J Immunother Cancer. 10:. PubMed
  55. Agrawal M, et al. 2021. Cells. 10:. PubMed
  56. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  57. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  58. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  59. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  60. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  61. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  62. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  63. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  64. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  65. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  66. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  67. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  68. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  69. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  70. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  71. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  72. Tondini E, et al. 2022. NPJ Vaccines. 7:64. PubMed
  73. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  74. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  75. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  76. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  77. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  78. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  79. Pilzecker B, et al. 2016. Nucleic Acids Res. 44: 4734 - 4744. PubMed
  80. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  81. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  82. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  83. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  84. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  85. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  86. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  87. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  88. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  89. White C, et al. 2015. J Immunol. 194:697. PubMed
  90. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  91. Chung L et al. 2018. Cell host & microbe. 23(2):203-214 . PubMed
  92. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  93. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  94. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  95. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  96. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  97. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  98. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  99. Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed
  100. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  101. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  102. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  103. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  104. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  105. Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed
  106. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  107. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
  108. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  109. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
  110. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  111. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  112. Shi R, et al. 2019. J Cancer. 10:367. PubMed
  113. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  114. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  115. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  116. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  117. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  118. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  119. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  120. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  121. Tang Y, et al. 2019. Nat Commun. 10:4157. PubMed
  122. Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
  123. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  124. Mezzapelle R, et al. 2021. EMBO Mol Med. 13:e12344. PubMed
  125. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  126. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  127. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  128. Woodring T, et al. 2022. iScience. 25:104934. PubMed
  129. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  130. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  131. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
  132. Highton AJ, et al. 2019. Wellcome Open Res. 4:78. PubMed
  133. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  134. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  135. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  136. Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed
  137. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  138. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  139. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  140. Bennion BG, et al. 2019. J Virol. 93. PubMed
  141. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  142. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  143. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  144. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  145. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  146. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  147. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  148. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  149. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  150. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  151. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  152. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  153. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  154. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  155. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  156. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  157. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  158. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  159. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  160. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  161. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  162. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  163. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  164. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  165. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  166. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  167. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  168. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  169. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  170. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  171. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  172. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  173. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  174. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  175. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  176. Goc J, et al. 2021. Cell. 184:5015. PubMed
  177. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  178. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  179. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  180. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  181. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  182. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  183. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  184. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  185. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  186. Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed
  187. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  188. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  189. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
RRID
AB_2075239 (BioLegend Cat. No. 100733)
AB_2075238 (BioLegend Cat. No. 100734)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 10.23.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account